Creating a highly sensitive test for detecting leftover leukemia cells in patients with Acute Myeloid Leukemia.
Official title: Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing
Funded at Twinstrand Biosciences, INC. · NIH-10907583 · Data updated 2026-11-12
This study is testing a new blood test that uses advanced technology to better find tiny amounts of leftover leukemia cells in patients with Acute Myeloid Leukemia, helping doctors create more personalized treatment plans and reduce the chance of relapse.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Twinstrand Biosciences, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 16, 2018 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,985,831 |
| NIH project number | 5R44CA233381-06 |
| Project ID | NIH-10907583 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia who have undergone treatment and are in a state of complete remission.
✕Less likely to help
Patients with other types of leukemia or those who have not been diagnosed with Acute Myeloid Leukemia may not benefit from this research.
What this research studies
This research focuses on improving the detection of minimal residual disease (MRD) in patients with Acute Myeloid Leukemia (AML) using a cutting-edge technology called Duplex Sequencing. Current methods for assessing remission may miss residual leukemia cells, which can lead to relapse. By utilizing Duplex Sequencing, the study aims to enhance the sensitivity of detecting these low-frequency mutations associated with residual leukemia, potentially allowing for more tailored and effective treatment strategies. Patients who participate may undergo blood tests that utilize this advanced sequencing technology to monitor their disease status more accurately.
Why it matters
Potential benefit: If successful, this research could lead to more precise monitoring of leukemia patients, potentially reducing relapse rates and improving survival outcomes.
How similar studies have gone: Previous studies have shown promise in using advanced sequencing technologies for similar applications, indicating a potential for success in this novel approach.
Where this research is happening
-
Twinstrand Biosciences, INC.
Seattle, United States Active
Researchers
- Principal investigator: Bickel, Kellie — Twinstrand Biosciences, INC.
- Study coordinator: Bickel, Kellie
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.